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Abstract Many components and pathways transducing
multifaceted and deleterious effects of stress stimuli remain
ill-defined. The Ran-binding protein 2 (RanBP2) interac-
tome modulates the expression of a range of clinical and
cell-context-dependent manifestations upon a variety of
stressors. We examined the role of Ranbp2 haploinsuffi-
ciency on cellular and metabolic manifestations linked to
tyrosine-hydroxylase (TH?) dopaminergic neurons and
glial cells of the brain and retina upon acute challenge to
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a
parkinsonian neurotoxin, which models facets of Parkinson
disease. MPTP led to stronger akinetic parkinsonism and
slower recovery in Ranbp2?/- than wild-type mice without
viability changes of brain TH?-neurons of either genotype,
with the exception of transient nuclear atypia via changes
in chromatin condensation of Ranbp2?/- TH?-neurons.
Conversely, the number of wild-type retinal TH?-amacrine
neurons compared to Ranbp2?/- underwent milder declines
without apoptosis followed by stronger recoveries without
neurogenesis. These phenotypes were accompanied by a
stronger rise of EdU?-proliferative cells and non-prolifera-
tive gliosis of GFAP?-Mu¨ller cells in wild-type than
Ranbp2?/- that outlasted the MPTP-insult. Finally, MPTP-
treated wild-type and Ranbp2?/- mice present distinct
metabolic footprints in the brain or selective regions thereof,
such as striatum, that are supportive of RanBP2-mediated
regulation of interdependent metabolic pathways of lysine,
cholesterol, free-fatty acids, or their b-oxidation. These
studies demonstrate contrasting gene-environment pheno-
deviances and roles of Ranbp2 between dopaminergic and
glial cells of the brain and retina upon oxidative stress-
elicited signaling and factors triggering a continuum of
metabolic and cellular manifestations and proxies linked to
oxidative stress, and chorioretinal and neurological disorders
such as Parkinson.
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Introduction
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a
neurotoxin that models multiple facets of Parkinson’s dis-
ease (PD) [1–4]. 1-methyl-4-phenylpyridinium (MPP?) is
the active metabolite of MPTP that is taken up by dopami-
nergic neurons [5], where it is thought to poison these by
inhibition of the mitochondrial complex I and generation of
superoxide anions [6, 7]. Previous experiments with mes-
encephalic neuronal cultures also supported that MPTP
could promote the displacement of dopamine from vesicular
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stores, leading then to the intracellular and extracellular
auto-oxidation of dopamine and production of reactive
oxygen species (ROS) [8]. The pathophysiological
relevance of these results are controversial, because
(i) dopaminergic neurons (DA) of mice lacking functional
Ndufs4, a subunit critical to the functional assembly of
complex I, are not protected to MPP? [9] and (ii) acute
administration of MPTP still induces neurotoxicity in DA
neurons of DA-deficient mice [10], whereas overexpression
of the dopamine transporter in striatal neurons of transgenic
mice lent support to the concept that impairment of intra-
cellular dopamine vesicular sequestration suffices to
promote neurodegeneration [11]. In addition to DA neuro-
nal degeneration, MPTP is also reported to induce gliosis
and microglial activation, events that are thought to con-
tribute to the injury of DA neurons [12, 13]. The effects of
MPTP and comparison of its pathophysiological outcomes
become more complex with the observations that rodents
are more resistant to MPTP neurotoxicity than primates and
the multivariate susceptibilities to MPTP treatment vary
significantly with mouse strains, sex, age, and treatment
modalities [12, 14–20].
The neuroretina also harbors TH?-amacrine neurons.
These DA neurons are the least numerous and the largest
neurons in the retina because of the large arborization fields
they present [21, 22]. Dopamine plays a role in light adap-
tation and PD patients suffer from various visual impairments
[23, 24]. MPTP treatment is also reported to reduce reversibly
or have no effect on the number of DA amacrine neurons and
these effects are accompanied by a decrease of the retinal
oscillatory potentials and activation of glial and microglial
cells and astrocytes [25–30]. Hence, collectively these results
support that the multifaceted and cell-context-dependent
responses elicited by the Parkinsonian neurotoxin, MPTP, are
susceptible to modulation by ill-characterized factors. Iden-
tification and characterization of such biological factors are of
considerable therapeutic value, because among other reasons
they may uncover disease-relevant pathways and serve as
pharmacological targets to promote neuroprotection.
The Ran-binding protein 2 (RanBP2) is known to modu-
late directly responses elicited by various deleterious
stressors, such as phototoxicity [31, 32], infectious agents
[33], and carcinogens [34]. In this regard, haploinsufficiency
of Ranbp2 confers neuroprotection to photoreceptor neurons
upon light-elicited oxidative stress [31, 32], whereas semi-
dominant mutations in human RANBP2 promote the rampant
necrosis of basal ganglia neurons triggered by febrile states
and viral infections of multiple etiologies [33]. Additionally,
haploinsufficiency or hypomorphism of Ranbp2 increases the
susceptibility to tumorigenesis in the presence of carcinogens
[34]. Parkin, whose loss-of-function causes PD in the human,
is reported to associate with RanBP2 [35]. Like Ranbp2,
parkin (PARK2) is also a tumor-suppressor gene [36]. Parkin
and RanBP2 exhibit E3-ubiquitin ligase activity and the
association of parkin with RanBP2 promotes the ubiquitina-
tion and degradation of RanBP2 [35, 37, 38]. Among other
locations, RanBP2 and parkin appear to localize to the
mitochondria, where parkin is thought to exert a neuropro-
tective role [39–42]. parkin-/- mice present deficits in lipid
and glucose metabolism and energy homeostasis [42, 43],
a phenotype that evokes manifestations observed with
haploinsufficiency of Ranbp2 [31, 40]. Hence, these data
collectively support that RanBP2 modulates stress signaling
pathways critical to neuronal viability and that RanBP2 and
parkin may share pathomechanisms of relevance to the sur-
vival or function of dopaminergic neurons. To further define
the role of deficits in RanBP2 in stress-mediated responses,
we explored in this study the role of haploinsufficiency of
Ranbp2 in brain and retinal tyrosine-hydroxylase (TH?)-
neurons and glial cells upon acute exposure to the Parkinso-
nian neurotoxin, MPTP, in an inbred mouse strain (129P2/
OlaHsd). We found significant multifaceted phenotypic and
metabolic footprint manifestations in the brain and retina
between inbred wild-type and Ranbp2?/- mice. These phe-
notypic outcomes may underlie phenodeviances and pathobi-
ological processes shared by diseases linked to oxidative
stress, including parkinsonian manifestations.
Materials and methods
Mice and drug administration
Animal protocols were approved by the Institutional Ani-
mal Care and Use Committee at Duke University and the
procedures adhered to the ARVO guidelines for the Use of
Animals in Vision Research and National Academy of
Sciences. Twenty-four to 28-week-old wild-type or Ran-
bp2?/- (Ranbp2?/Gt(pGT0pfs)630Wcs) male mice previously
generated with an identical inbred 129P2/OlaHsd genetic
background were employed [40]. Mice were housed in a
temperature-controlled and pathogen-free transgenic bar-
rier facility in a standard 12:12 h light–dark cycle at \70
lux and given ad libitum access to water and breeder chow
diet 5LJ5 (Purina). Mice received four bolus i.p. injections
of MPTP.HCl (20 mg/kg, Sigma) in physiological saline at
2-h intervals and the first injection was administered
9:00–10:00 a.m. Mice were kept in isolation until being
killed. For these studies, all mice were killed by cervical
dislocation followed by decapitation at either 6 or 14 days
after MPTP treatment.
Open-field test
Mice were transferred separately to a 46 9 42 cm Plexi-
glas box with the bottom marked with a 25-square grid.
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Mice motility was recorded daily in isolation for 15 min;
data were analyzed by counting the number of quadrants
each mouse traveled within a constant time period.
EdU administration, labeling, and staining
For cumulative EdU (5-ethynyl-20-deoxyuridine, Invitro-
gen) labeling [44], mice received a daily bolus of EdU by
i.p. injection (100 ll of 1 mg ml-1 EdU) during the first 6
or 13 days immediately following the last MPTP bolus or
from days 9 to 13 after MPTP treatment. Mice were killed
at days 6 or 14 after MPTP treatment. Development of EdU
staining was performed always after incubation of sections
or flatmounts with primary antibodies against cell markers
and secondary antibodies. After incubation with the sec-
ondary antibody, brain and retinal sections or retinal
flatmounts were fixed with 4 % paraformaldehyde in PBS
solution for 15 min, washed once with 3 % BSA in
100 mM PBS, followed by permeabilization with 100 mM
PBS, pH 7.4/0.5 % Triton X-100 for 20 min. Finally,
specimens were incubated with the EdU detection cocktail
for 30 min as per the manufacturer’s instructions (Click-
iT EdU Alexa 488 Imaging Kit, Invitrogen, Carlsbad, CA,
USA).
Immunohistochemistry reagents
List of primary and secondary antibodies are described in
Supplementary Materials and Methods.
Tissue collection for morphological and morphometric
analyses
Collection, processing, and immunostaining of brain and
retina specimens for morphometric analyses are described
in detail in Supplementary Materials and Methods.
Immunohistochemistry
Free-floating 50-lm coronal sections of selected brain
regions, 12-lm frozen retinal sections mounted on slides or
flat-mount retinas were incubated in blocking buffer (PBS,
pH 7.4, containing 0.1 % Triton X-100, 10 % normal goat
serum) at room temperature for 1 h followed by an incu-
bation with primary antibody in incubation buffer (PBS,
pH 7.4, containing 0.1 % Triton X-100, 5 % normal goat
serum) overnight at room temperature (brain) or 4 C
(retina). After three times of washing with washing buffer
(PBS with 0.1 % Triton X-100) for 10 min, specimens
were incubated in incubation buffer for 2 h with one or
more Alexa-conjugated secondary antibody (1:1,000;
Invitrogen, Carlsbad). Specimens were washed three times
with washing buffer and whenever applicable mounted on
glass slides for visualization and image acquisition with a
Nikon 90i C1 Plus confocal microscope.
TUNEL assays
Detection of apoptosis was carried out in situ in brain and
retinal sections with the DeadEnd Fluorimetric TUNEL
System (Promega) exactly as described elsewhere [31].
Metabolomic profiling
Unbiased metabolomic profiling of whole brains of wild-
type and Ranbp2?/- mice 6 days after MPTP treatment
was performed by Metabolon, Inc. (Durham, NC). Brains
were immediately stored at -80 C after dissection and
upon discarding the olfactory bulb and cerebellum. The
brains were then provided to Metabolon, Inc. Additional
metabolomic methodologies employed by Metabolon are
described in Supplementary Materials and Methods.
Biochemical assays
Immediately after the mice were killed, tissues were col-
lected, snap frozen in liquid nitrogen, and stored at -80 C
in a freezer. Liver, midbrain, and striatum tissue extracts in
250 ll of NP-40 were prepared using Precellys 24 dual
tissue homogenizer (Bertin Technologies, Montignyle-
Bretonneux), at 6,000 rpm for 23 s. Total cholesterol, free
cholesterol, and esterified cholesterol were measured as
previously described [31]. Levels of Coenzyme A were
determined by the Coenzyme A Assay Kit (Biovision,
Mountain View, CA, USA) as directed by the manufac-
turer. Results were normalized against protein amounts in
NP40 tissue extracts used for each assay. Two-sample t test
statistical analyses with the assumption of unequal variance
were performed; p B 0.05 was defined as significant.
Results
Haploinsufficiency of Ranbp2 causes increased
akinesia and slow recovery upon MPTP treatment
To assess the effects of MPTP on dopaminergic neurons
and glial cells of the brain and retina of wild-type and
haploinsufficient Ranbp2 mice, 24-week-old inbred mice
were subjected to a protocol of acute exposure of MPTP
followed by time-course examination of their motility in an
open-field test, state of TH?-neurons and glial cells of the
brain and retina, and changes in brain metabolites (Fig. 1).
As shown in Fig. 2a, there were no significant differences
in basal locomotors activity between wild-type and Ran-
bp2?/- mice the day before MPTP treatment began, but
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there was a stronger decline followed by a slower recovery
phase in Ranbp2?/- than wild-type mice after MPTP
treatment. Further, not all Ranbp2?/- compared to wild-
type mice recover their motility at the end of the 14-day
experimental procedure (Fig. 2b).
MPTP promotes transient nuclear atypia in brain
TH?-neurons of Ranbp2?/- mice
We then performed morphometric analyses of coronal
sections between wild-type and Ranbp2?/- mice of cell
bodies of TH?-neurons at the end of the 14-day experi-
mental procedure and encompassing the following regions
of the mesencephalic dopaminergic network: such as sub-
stantia nigra pars compacta (SNc), ventral tegmental area
(VTA), locus coeruleus (LC), and periaqueductal gray area
(PAGA) (Fig. 3a, b). We found no significant changes in
the number of TH?-neurons between non-treated and
treated mice of either genotype. We also examined the
striatum, which contains axons and synaptic terminals of
the TH?-neurons, for density changes of TH?-axons and -
synaptic terminals. No remarkable differences in TH?-
neurons were detected between treated mice of either
genotype at 6 or 14 days after MPTP treatment (Supple-
mental Fig. 1). There was no evidence of apoptosis in all
areas of the mesencephalic dopaminergic network by
TUNEL assay (data not shown). Likewise, there was no up-
regulation of glial fibrillary acidic protein (GFAP)
throughout the brain sections examined, a process com-
monly elicited by neuronal injuries of multiple etiologies
(data not shown) [45, 46]. The only distinct morphological
difference was the development of nuclear atypia in TH?-
neurons at 6 days after MPTP treatment that was signifi-
cantly more pronounced in Ranbp2?/- than wild-type mice
(Fig. 4a, b). The nuclear compartment became hypotrophic
as reflected by the prominent and asymmetric clumping of
DAPI-stained chromatin of TH?-neurons of Ranbp2?/-
mice towards an edge of the nuclear compartment
(Fig. 4a). These abnormalities disappear, however, by day
14 post-MPTP-treatment, since no differences in the
nuclear distribution of DAPI-stained chromatin could be
observed with mice of either genotype (Fig. 4a).
MPTP promotes distinct effects between TH?-neurons
and GFAP?-glia in retinae of wild-type and Ranbp2?/-
mice
We also examined the effect of MPTP on TH?-amacrine
neurons of the retina, since apparently conflicting reports
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Fig. 1 MPTP treatment and experimental time line. The baseline
motor activities of wild-type and Ranbp2?/- mice were assessed the
day prior to the MPTP treatment (Day -1). Wild-type and Ranbp2?/-
mice on an inbred 129P2/OlaHsd background underwent four bolus
of MPTP i.p. injections spaced 2 h apart. The motor activities of the
mice were assessed daily; brain and retinal tissues were collected for
analyses at days 6 and 14 after MPTP treatment. Metabolic profiling






































































Fig. 2 Motor activities of wild-type and Ranbp2?/- mice before and
after MPTP treatment. a Motor activities between wild-type and
Ranbp2?/- mice during the first 7 days after MPTP treatment. Wild-
type and Ranbp2?/- mice exhibit no significant differences in basal
motor activities a day prior to the initiation of MPTP treatment (day
-1). The decline in motility reached its peak at the second day post-
treatment and it plateaued for about 2 days before mice of both
genotypes began to regain steadily their motilities. The greatest
difference in motility between genotypes was observed at day 6 after
MPTP treatment. b The recovery of the motility of wild-type mice is
significantly faster than Ranbp2?/- mice. Data shown represent the
mean ± SD; p \ 0.002, n = 5 (a); p = 0.04, n = 6 (b). Black and
white bars represent wild-type and Ranbp2?/- mice, respectively. n.s.
not significant (p [ 0.05); ?/? wild-type, ?/- Ranbp2?/-
3514 K. Cho et al.
123
dopaminergic neurons upon MPTP treatment. No significant
differences in the number of TH?-amacrine neurons exist
between untreated wild-type and Ranbp2?/- mice (Fig. 5a).
After 6 days of MPTP treatment, however, there were less
TH?-amacrine neurons in both genotypes, but such a
decrease was greater in Ranbp2?/- than wild-type mice
(Fig. 5a). Such a decrease was not caused by the cell death of
TH?-amacrine neurons, because we could not detect any
TUNEL-positive cells in the inner nuclear or any other
retinal nuclear layers (data not shown). Notably, the number
of TH?-amacrine neurons of Ranbp2?/- recovered to levels
comparable to those of non-treated mice by day 14 post-
MPTP treatment, while in wild-type mice they exceeded by
*20 % those observed in non-treated mice (Fig. 5a). In
association with this compensatory response, there was an
increase of the thickness and intensity of synaptic plexus of
TH?-amacrine neurons and the presence of weak immuno-
reactive TH?-neurons surrounding typically a strongly
+/+










































































































































































Fig. 3 MPTP does not cause the loss of dopaminergic neurons in
various regions of the brain in wild-type and Ranbp2?/- mice.
a Confocal images of TH?-dopaminergic neurons of the substantia
nigra pars compacta (SNc), ventral tegmental area (VTA), and locus
coeruleus (LC). b Morphometric analyses show no differences in the
number of cell bodies of dopaminergic neurons of the SNc, VTA, LC,
and periaqueductal gray area (PAGA) between non-treated and
MPTP-treated wild-type and Ranbp2?/- mice. Data shown represent
the mean ± S.D, *p [ 0.05, n = 5; MPTP-treated mice; n = 3, non-
treated mice. MPTP-treated mice were analyzed 6 days after MPTP
treatment. Cell body tallying reflects 18 coronal topographically
equivalent sections of 50 lm from various regions of each brain
hemisphere of wild-type and Ranbp2?/- mice. ?/? wild-type,
?/-Ranbp2?/-, NT non-treated; scale bars 150 lm
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stained TH?-amacrine neuron in MPTP-treated wild-type,
but not treated Ranbp2?/- and non-treated mice (Fig. 5b). It
is noteworthy that these weak immunoreactive cells were
never counted for the quantitative analyses described earlier.
Likewise, these effects were accompanied by an increase in
the staining of the dopaminergic synaptic plexus for the
vesicular monoamine transporter-2 (VMAT2) (Fig. 5c).
These changes were also highly selective toward TH?-
amacrine neurons, because no significant changes were
observed in calretinin immunostaining of AII amacrine cells
and sublaminar synaptic layers of the inner plexiform layer
and Cabp5 immunostaining of rod and cone bipolar neurons
in the inner nuclear layer (data not shown).
Stress stimuli of multiple etiologies and causing retinal
damage are known to induce the up-regulation of glial
fibrillary acidic protein (GFAP) in Mu¨ller glial cells [46].
Further, these glial cells are thought to present proliferative
capacity and few appear to regenerate into amacrine neu-
rons [46]. Hence, we examined whether MPTP treatment
promoted changes in the density of GFAP?-radial glia
(Mu¨ller cells) of the retina and these cells were the source
of the increase in the number TH?-amacrine neurons in
MPTP-treated wild-type mice. No remarkable changes of
GFAP?-Mu¨ller cells were seen before and at day 6 after
treatment in wild-type and Ranbp2?/- mice compared to
non-treated mice (Fig. 6a, upper panel; data not shown).
However, there was a robust and significant rise of
GFAP?-glial cells in retinas of wild-type, but not Ran-
bp2?/- mice, at day 14 after MPTP-treatment (Fig. 6a) that
was most prominent and significant toward the marginal
regions of the retinas (Fig. 6a, lower panel; b), even though
Mu¨ller cells immunostained for its canonical glial marker,
a
































Fig. 4 Ranbp2 haploinsufficiency promotes transient nuclear atypia
of TH?-dopaminergic neurons upon MPTP treatment. a Confocal
images of SNc TH?-dopaminergic neurons (red) of wild-type and
Ranbp2?/- mice counterstained with DAPI at 6 and 14 days after
MPTP treatment. Note the asymmetric distribution of clumped
chromatin and large nuclear areas voided of DAPI staining (nuclear
vacuolization) in Ranbp2?/-, but not wild-type mice, at 6-day post-
MPTP treatment. These phenotypic differences between genotypes
disappear at 14-day post-MPTP treatment. Inset pictures large
magnifications of cell bodies of TH?-dopaminergic neurons denoted
by arrows. Scale bars 10 lm. b Quantitative analysis of nuclear
atypia of TH?-dopaminergic neurons between wild-type and Ran-
bp2?/- mice at 6-day post-MPTP treatment. Data shown represent the
mean ± SD, p = 0.04, n = 3. ?/? wild-type, ?/- Ranbp2?/-
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glutamine synthetase, were distributed evenly throughout
the retina regardless of the genotype (Fig. 6c). By contrast,
the rise of GFAP?-Mu¨ller cells in treated Ranbp2?/- mice
is very tenuous, with only a few GFAP?-Mu¨ller cells
observed at the very marginal and optic nerve head regions
of the retina (Fig. 6a, b). Hence, RanBP2 insufficiency
suppresses gliosis upon MPTP challenge and this effect
outlasts the neurotoxic insult without affecting the general
distribution and viability of Mu¨ller glial cells.
Haploinsufficiency of Ranbp2 suppresses
the proliferation of EdU?-cells in the retina
that do not regenerate into TH?-amacrine neurons
upon MPTP treatment
The suppression of the recovery phase of TH?-amacrine
neurons in Ranbp2?/- mice at days 6 and 14 after MPTP
treatment (Fig. 5a) hints that insufficiency of RanBP2


































































Fig. 5 MPTP elicits a stronger decrease and a slower recovery of the
number of retinal TH?-neurons in Ranbp2?/- than wild-type mice.
a Comparison of the number of TH?-neurons in the retina between
Ranbp2?/- and wild-type mice before and after MPTP treatment (6
and 14 days post-treatment). Note the stronger recovery of retinal
TH?-neurons in wild-type mice 14 days after MPTP treatment
surpasses the number of TH?-neurons observed in non-treated wild-
type or Ranbp2?/- mice. Data shown represent the mean ± SD;
n = 6, MPTP-treated mice; n = 3, non-treated mice. b Confocal
images of retinal TH?-neurons (red) in non-treated (NT) and 14-day
post-MPTP treated wild-type and Ranbp2?/- mice. Note the increase
of the thickness of the TH?-synaptic plexus and the presence of
weakly stained TH?-cell bodies surrounding a strongly stained TH?-
amacrine cell body (inset picture) in wild-type mice 14 days after
MPTP challenge. These weakly stained TH?-cell bodies were never
observed in retinas of Ranbp2?/- mice. c The increase of the
thickness of the TH?-synaptic plexus was accompanied also by a
stronger increase of VMAT2 staining (green) in wild-type than
Ranbp2?/- mice. ?/? wild-type, ?/- Ranbp2?/-; scale bars 25 lm
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capable of regenerating into TH?-amacrine neurons or the
differentiation of existing cells by the up-regulation of
dopaminergic markers. Hence, we analyzed retinas of mice
that underwent MPTP treatment and three different
regimens of injections with the thymidine analog, 5-ethy-
nyl-2-deoxyuridine (EdU), which incorporates into
the DNA of proliferative cells [44]. The EdU modality
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5 days, between days 9 and 13, or throughout the 13 days
of the experimental procedure. Retinas were then analyzed
the day after the last EdU injection. Quantitative analyses
of confocal images scanned across a 50-lm depth of the
mid-plane of flatmount retinas of 5-day EdU-treated mice
showed that Ranbp2?/- had a significantly less number of
EdU?-cells than wild-type mice (Fig. 7a). Such a geno-
type-dependent decrease of proliferating cells was also
qualitatively observed with the other two regimens of EdU-
treatment. Regardless of the EdU-regimen modality and
genotype, we never detected co-labeling of single TH?-
amacrine neurons with EdU (Fig. 7b). These data support
that the changes in the number of TH?-amacrine neurons
result from the genotype-dependent modulation of
expression of TH, and possibly of other dopaminergic
markers, such as VMAT2, rather than from the prolifera-
tion of progenitor cells.
We then examined the identity of the EdU?- cells, whose
proliferation was suppressed in Ranbp2?/- mice upon
MPTP treatment, with antibodies against antigens known to
be either expressed in retinal progenitor cells or markers up-
regulated in proliferating cells upon retinal injury. In par-
ticular, Sox2 is known to be required for differentiation of
progenitor cells to amacrine and other retinal neurons [47],
whereas GFAP, CD45, and CD11b are markers for Mu¨ller
glia and astrocytes, vascular (leukocytes), and resting and
activated microglia and macrophages, respectively [48–50].
GFAP?-, CD45?-, and CD11b?-cells are known to prolif-
erate upon retinal damage to various stress stimuli [50–52].
As shown in Fig. 7c–f, most cellular markers tested were
expressed in EdU- cells, albeit with some differences.
Among the GFAP? cells, only very few were EdU?, thus
supporting GFAP?-cells represent a small fraction of
EdU?-proliferating cells (Fig. 7c). In the retina, all CD45?
were EdU- (Fig. 7d) and the few CD45?EdU? identified in
several sections were exclusively localized in the choroid
plexus (Fig. 7e). All CD11b? cells identified were EdU--
cells and they appeared to be macrophages that were also
exclusively localized in the choroid plexus (Supplementary
Fig. 2). Finally, we did not identify EdU?-Sox2 cells
(Fig. 7f). Hence, the majority of the EdU?-cells in the
retina represents cells of novel origin or identity.
Ranbp2-dependent metabolic imbalances in the brain
upon exposure to acute MPTP treatment
In light of the temporal differences in behavioral and cel-
lular phenotypes observed between inbred wild-type and
Ranbp2?/- mice upon MPTP treatment, we took an unbi-
ased metabolomic approach to examine differences in
metabolite profiles that contribute to genotype-dependent
manifestations outlasting the effects of MPTP. We
employed brain tissue without the olfactory bulb and cer-
ebellum, because of the amount of tissue needed to perform
metabolomic analysis, a requirement the retinal tissue does
not meet, and no differences in the gross cellular compo-
sition of the brain were observed between mice of either
genotype, an outcome that would otherwise skew the
metabolic profile. We performed metabolomics on mice
6 days after MPTP treatment, because this was the time
point when there was the greatest difference in locomotor
activity between wild-type and Ranbp2?/- mice (Fig. 2a).
This metabolomic approach led to the identification of 17
metabolites, which were significantly altered between
treated wild-type and Ranbp2?/- mice with an identical
inbred 129P2/OlaHsd genetic background (p \ 0.05)
(Fig. 8a), and of another 13 metabolites, which narrowly
missed the p \ 0.05 cutoff (e.g., hippurate, myo-inositol,
homocarnosine, phosphopantetheine with p = 0.0535,
0.0538, 0.0618, and 0.066, respectively) or with trends
approaching significance (0.05 \ p \ 0.10) (Fig. 8b). The
inclusion of trend differences further aided the interpreta-
tion of changes in metabolites and metabolic pathways
deemed to undergo significant changes.
The variations in metabolites observed between geno-
types upon MPTP treatment could be divided into five
major groups based on the role(s) and mapping of a set of
metabolites into metabolic pathways according to the
Kyoto Encyclopedia of Genes and Genomes (KEGG)
(Fig. 9). The first group comprises three metabolite sub-
sets, whose levels are thought to affect interdependent
metabolic pathways. The first subgroup is characterized by
a decrease of lipid metabolites or precursors thereof
(Figs. 8, 9a). In particular, we found a significant decrease
of two essential medium-chain free fatty acids, pelargonate
Fig. 6 Ranbp2 haploinsufficiency suppresses MPTP-elicited gliosis
in the retina. a Non-treated mice exhibit extremely weak GFAP
staining of Mu¨ller cells across the retina. In contrast, there is a
prominent centrifugal increase of the number of GFAP?-Mu¨ller cells
in retinas of MPTP-treated wild-type mice that are strongly decreased
in Ranbp2?/- mice 14 days after MPTP treatment. Strong GFAP
immunoreactivity is also observed in the optic nerve head (ON). Inset
pictures denoted by the arrows are high magnifications of boxed
peripheral or central regions of the retina. b Quantitative analyses of
immunofluorescence intensity of GFAP?-Mu¨ller cells in central and
peripheral regions of retinas of wild-type and Ranbp2?/- mice
14 days after MPTP treatment (as shown in a). Data shown represent
the mean ± SD; n = 3. c The significant differences in the density of
GFAP?-Mu¨ller cells observed between wild-type mice and Ran-
bp2?/- mice in a are not accompanied by differences in staining of
the canonical glial (Mu¨ller) marker, glutamine synthetase, which, in
contrast to GFAP, stains uniformly the glial cells across the retina.
Inset pictures denoted by the arrows are high magnifications of
peripheral or central regions of the retina. ?/? wild-type, ?/-
Ranbp2?/-, A.U. arbitrary units, ON optic nerve head; scale bars
200 lm
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Fig. 7 Retinal cellular proliferation elicited by MPTP is suppressed
by insufficiency of RanBP2 and it lacks canonical dopaminergic,
inflammatory, and vascular cellular markers. a The decrease of the
number of TH?-amacrine neurons is accompanied by a strong
decrease of EdU?-proliferating cells in Ranbp2?/- compared to wild-
type mice 6 days after MPTP treatment. Data shown was collected
from images of flat-mount retinas and represent the mean ± SD;
n = 4, wild-type; n = 5, Ranbp2?/-. b 3-D reconstruction of
confocal x-y-z image stacks across a 50-lm depth of the inner
nuclear and plexiform layers of the retina and depicting the non-
overlapping spatial arrangement of cell bodies of TH?-amacrine
neurons (red) and EdU?-cells (green) 6 days after MPTP treatment in
wild-type and Ranbp2?/- mice. Ranbp2?/- mice present far fewer
EdU?-cells than do wild-type mice. The images below the 3-D images
are 2-D cross sections of collapsed 3-D images. Scale bars:
x 635.5 lm, y 635.5 lm, z 50 lm with cell bodies of TH?-amacrine
neurons occupying the mid-plane of the z-stack. c Only few GFAP?-
cells (red) in the retina were co-labeled by EdU (green) in wild-type
mice; GFAP?-cells are shown with (arrow) and without (arrowhead)
EdU labeling. d No CD45?-cells (red, arrowhead) in the retina were
observed to be labeled by EdU (green, arrow) in mice of either
genotype, although in the choroid plexus few CD45?-cells were co-
labeled by EdU (arrow) (e). f No Sox2?-cells (red, arrowhead) in the
retina were observed to be labeled by EdU (green, arrow) in mice of
either genotype. Images c–f are representative retinal sections of mice
provided with a daily EdU bolus for 13 days after MPTP treatment.
?/? wild-type, ?/- Ranbp2?/-
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(9:0) and caprate (10:0) (0.85-fold), and the long-chain free
fatty acid, arachidate (20:0) (0.75-fold) in Ranbp2?/- mice.
Likewise, there is a strong and significant decrease in
lathosterol (0.53-fold), a canonical whole-body indicator
of cholesterol synthesis [53, 54]. Indeed, a significant
decrease of cholesterol levels (0.61-fold) was observed.
These deficits were also accompanied by a trend for a
decrease of the levels of phosphopantetheine (0.63-fold), a
key precursor for the synthesis of the cofactor, coenzyme
(CoA), which is critical for the synthesis of free fatty
acids and cholesterol [55]. It is of interest to note that the
fold-changes in levels of CoA and one of its intermedi-
ate precursors, 30-dephosphocoenzyme A, had the same
magnitude of phosphopantetheine (0.63-fold), even though
the differences of the mean levels of 30-dephosphocoen-
zyme A and CoA between genotypes were not statistically
significant.
The second subset comprises a significant rise in Ran-
bp2?/- mice of the levels of several carnitine conjugates, such
as 3-dehydrocarnitine (1.6-fold) and glutaroyl carnitine
(1.87-fold), and a trend for an increase in propionylcarnitine
(1.55-fold). These surges are also accompanied by an increase
of 2-aminoadipate (2.13-fold), an intermediate in lysine
metabolism. The rise of the metabolites of this group is likely
due to an increase of lysine catabolism, because of increases in
the levels of 2-aminoadipate, 3-dehydrocarnitine, and gluta-
royl carnitine. Further, odd-chain acylcarnitines, such as
propionylcarnitine (C3), are produced during amino acid
catabolism [56]. Interestingly, we found the levels of several
other acylcarnitines, such as butyrylcarnitine, acetylcarnitine,
palmitoylcarnitine, stearoylcarnitine, and oleoylcarnitine, to
be elevated in Ranbp2?/- mice. The changes in these acyl-
carnitines levels represented some of the greatest fold
increases of this study (from 1.55- to over threefold) and there
was a significant correlation between their elevated levels in
Ranbp2?/- mice (rs [ 0.9; p \ 0.037) even though the dif-
ferences of the mean levels of each between genotypes were
not significant. Acylcarnitines transport long-chain and
medium-chain fatty acids into the mitochondria for energy
generation via b-oxidation and together with reduced levels of
coenzyme A, they likely contribute to the accumulation of
acylcarnitines [57].
Finally, the last subgroup is characterized by signifi-
cant increases of glycerophosphorylcholine (1.48-fold),
glucose (1.76-fold), lactate (1.36-fold), nicotinamide ade-
nine dinucleotide (NAD?) (1.45-fold), and dehydroascorbate
(2.1-fold). These changes are accompanied also by increased
trends of the levels of glycerol 3-phosphate (1.54-fold),
myo-inositol (1.22-fold), and threonate (1.78-fold). Alto-
gether, the accumulation of these metabolites may arise from
an impairment of the glycerophosphate shunt and reduced
anaplerosis of the Krebs cycle [58]. Glycerophosphoryl-
choline and myo-inositol are also cellular osmolytes with
important roles in maintaining cellular volume in response to
hypertonic stress [59].
The rise in lysine catabolism in Ranbp2?/- mice also
correlates directly with changes in a second group of
metabolites, 1-methylimidazoleacetate (t-MIAA; 1.43-fold)
and homocarnosine/c-aminobutyryl-L-histidine (0.81-fold)
(Figs. 8, 9b). The significant increase of the former results
from the enhanced catabolism of histidine to histamine and
it is a reliable marker of histamine turnover rate [60] and
such augmented conversion likely induces a decrease of the
levels of the dipeptide homocarnosine [61]. This dipeptide
is formed from c-aminobutyric acid (GABA) and histidine,

























































































Fig. 8 Metabolomic alterations between Ranbp2?/- and wild-type
mice upon MPTP treatment. a Fold-changes in brain metabolites of
Ranbp2?/- relative to wild-type mice 6 days after the acute MPTP
insult. Data represent the mean ± SD and metabolites with significant
variations (Wilcoxon p \ 0.05), n = 5 for all metabolites but BC,
DA, Lac, GSH, and Ch (n = 5, wild-type; n = 4, Ranbp2?/-), G
(n = 4, wild-type; n = 5, Ranbp2?/-) and NAD? (n = 4). b Fold-
changes in brain metabolites of Ranbp2?/- relative to wild-type mice
6 days after MPTP challenge that narrowly missed or approached
statistical significance (Wilcoxon 0.1 \ p \ 0.05). Data represent the
mean ± SD, n = 5. Black and grey bars represent higher and lower
levels of metabolites in Ranbp2?/- relative to wild-type mice,
respectively. GPC glycerophosphorylcholine, 1-MIA 1-methylimi-
dazoleacetate, 3-DC 3-dehydrocarnitine, GC glutaroyl carnitine, 2-AA
2-aminoadipate, 20:0 arachidate, 9:0 pelargonate, 10:0 caprate, LS
lathosterol, Ade adenine, DA dehydroascorbate, BC butyrylcarnitine,
G glucose, L lactate, NAD? nicotinamide adenine nucleotide, GSH
glutathione (reduced), Ch cholesterol, 1-LGPC 1-linoleoylglycero-
phosphocholine, 1-SGPC 1-stearoylglycerophosphocholine, DPG 1,3-
dipalmitoylglycerol, PP phosphopantetheine, HP hippurate, HC
homocarnosine, TH threonate, myo-I myo-inositol, 5-MTA 5-methyl-
thioadenosine, Pcar propionylcarnitine, G3P glycerol 3-phosphate,
XT xanthosine, Lac lactate, OP ophthalmate
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GABA reservoir, the main neurotransmitter inhibitor of the
brain. Notably, the immediate precursor of t-MIAA, meth-
ylimidazole acetaldehyde, is the metabolite of the oxidative
deamination of N-methylhistamine by the monoamine
oxidase type B (MAO-B), which also metabolizes dopa-
mine upon its oxidative deamination and converts MPTP to
MPP?. MAO-B is also a therapeutic target for Parkinson’s
disease.
The third group reflects a rise of metabolites of the
methionine and adenine salvage pathways in Ranbp2?/-
mice (Figs. 8, 9c). There was a significant 1.4-fold increase
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S-benzoate-CoA + glycine Hippurate + CoA
e
Fig. 9 Model of metabolic deregulation in the brain by RanBP2
insufficiency upon MPTP insult. Alterations of brain metabolites by
RanBP2 insufficiency upon acute MPTP exposure were subdivided
into five major groups (a–e). Metabolites of group a participate in
depicted multistep and interdependent metabolic pathways regulating
bioenergetics in the cytosol or mitochondria related to lipid and
glucose metabolism and cofactors thereof. These metabolites can be
further divided into three subsets: lipid metabolites or precursors and
cofactors thereof, acylcarnitine conjugates and metabolites of lysine
catabolism, bioenergetic metabolites/substrates, and cofactors thereof
(e.g., glycerophosphorylcholine, glucose, lactate, NAD?) that likely
promote reduced anaplerosis of the Krebs cycle. Metabolites of group
b reflect changes in histidine catabolic pathways, whereas those of
group c represent variations in the methionine and adenine salvage
pathways. Metabolites of groups d and e represent changes in
conjugation reactions with glycine, reflecting variations of redox
pathways (group d) and detoxification reactions (group e). See text for
further details. Metabolites in red and green are, respectively, up-
regulated and down-regulated; single and multiple arrows represent
single and multi-step pathways. MAO-B monoamine oxidase, type B
ORC1 ornithine carrier, CPTII carnitine palmitoyltransferase II, ODC
oxodicarboxylate carrier, OGC oxoglutarate carrier
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of the levels of 5-methylthioadenosine (1.32-fold) and
xanthosine (1.32-fold). Finally, the fourth and fifth groups
are represented by the metabolites, reduced glutathione
(GSH) (0.65-fold) and ophthalmate (1.47-fold), and hippu-
rate (0.59-fold), respectively (Figs. 8, 9d, e). Ophthalmate
and hippurate metabolites arise from the conjugation
reactions with glycine. Hippurate is a common metabolite
of detoxification reactions [62]. Ophthalmate is a tripeptide
analogue of glutathione and a useful biomarker of redox
state and oxidative damage of tissues when it is accompa-
nied typically by depletion of reduced glutathione (GSH)
[63]. We found that lower levels of GSH were accompanied
by a trend of higher levels of ophthalmate. Further, it is of
interest to note that the glutathione cycle is also coupled
with the GABA shunt (synthesis of c-aminobutyrate) [64],
thus changes in the levels of metabolites of glutathione
cycle are likely to contribute to compound biochemical
phenotypes.
The depressed levels of selective free fatty acids species
and the accumulation of several acylcarnitine species in the
brain of Ranbp2?/- mice may result in part from changes
in the limited free pool of CoA or intermediates thereof in
the cytosol and mitochondria. Hence, we examined whe-
ther there were tissue differences in deficits of CoA in the
liver, the major organ of CoA synthesis, the striatum,
where the uptake and accumulation of MPP? takes place,
and the midbrain, where a large number of dopaminergic
cell bodies (e.g., substantia nigra) are clustered. We found
the levels of CoA to be decreased over twofold in the
striatum of Ranbp2?/- mice, but not changed in the mid-
brain and liver (Fig. 10).
Discussion
The data support that a difference in genetic dosage of
Ranbp2 in the inbred 129P2/OlaHsd genetic background
modulates significant metabolic pathways in the brain
without causing significant nigrostriatal cellular changes
upon acute MPTP exposure. In contrast, a variety of cell
types of the retina undergo significant cellular changes upon
Ranbp2 haploinsufficiency and MPTP exposure with the
most striking effects observed by the suppression of the
following cellular manifestations: (i) gliosis of GFAP?-
Mu¨ller cells outlasting the xenobiotic insult, (ii) recovery of
TH?-amacrine neurons and (iii) activation of a heteroge-
neous population of proliferative cells across the retina. This
study also uncovers a distinct and large proliferative popu-
lation of cells elicited by MPTP that differ from those
reported for other neurotoxicity models, such as intraocular
injection of N-methyl-D-aspartic acid (NMDA) with or
without selective growth factors, glutamate, or a-aminoad-
ipate [65–67]. NMDA together with retinoic acid induces
the regeneration of a restricted number of Mu¨ller cells into
bipolar or photoreceptor cells, whereas NMDA in the
presence of EGF, FGF1, or FGF1 combined with insulin,
stimulates the production of Mu¨ller glia with a small frac-
tion of these regenerating into undefined amacrine neurons
[65, 66]. However, glutamate or a-aminoadipate, which was
found in this study to be significantly elevated in Ran-
bp2?/-, promotes the transient proliferation of Mu¨ller glial
cells and differentiation into retinal neurons, such as pho-
toreceptors [67]. By contrast, our study found that MPTP
elicits long-lasting retinal gliosis by dramatically up-regu-
lating resident GFAP?-Mu¨ller cells without the majority of
these cells undergoing proliferation. Further, we did not
identify any MPTP-elicited EdU?-proliferating cells with
the capacity to regenerate into TH?-amacrine neurons even
though most were localized to the inner retina. Instead,
MPTP promotes the transient suppression of TH expression
in dopaminergic amacrine neurons followed by marked and
compensatory recoveries of TH expression in such neurons,
a finding that is consistent with the work reported by Tatton
et al. [25]. Hence, the data imply the existence of distinct
cellular and molecular responses to MPTP-neurotoxicity
between TH?-neurons of the brain and the retina. These data
support the existence of distinct TH?-neuronal subtypes
between these tissues and RanBP2- and microenvironment-
dependent trophic signaling between unique populations of
MPTP-activated and proliferative glia in the brain and
retina.
These data also support the existence of a novel popu-
lation of EdU?-proliferating cells elicited by MPTP and
repressed by Ranbp2 haploinsufficiency. In contrast to
other inflammatory models of neurotoxicity and injury to
the retina [50–52, 68], the EdU?-proliferating cells elicited
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Fig. 10 Haploinsufficiency of Ranbp2 selectively causes a decrease
of the levels of CoA in the striatum upon MPTP insult. CoA levels
were decreased selectively in the striatum of Ranbp2?/- mice relative
to wild-type mice 6 days after the acute MPTP insult. No changes of
CoA levels were observed in the midbrain and liver. Data shown
represent the mean ± SD; n = 4, wild-type; n = 5, Ranbp2?/-.
Black and white bars represent wild-type (?/?) and Ranbp2?/-
(?/-) mice, respectively
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by MPTP and resident in the retina were neither CD45?
nor CD11b? and the former cells were never detected
in retinas of Ranbp2?/- mice. Instead, CD45?EdU- and
CD45?EdU? cells were only detected in the choroid (vas-
cular) plexus of Ranbp2?/- mice, whereas CD11b? cells
were exclusively present in the choroid plexus and they
were all EdU-. Altogether, these data strengthen the notion
of the development of distinct and antagonistic phenotypic
outcomes observed between cell types by Ranbp2 insuffi-
ciency upon other disease stressors, such as phototoxicity
[31, 32] and carcinogen exposure [34]. For example, the
increased carcinogen-induced cellular proliferation (e.g.,
tumorigenesis) upon Ranbp2 insufficiency contrasts sharply
with the suppression of the MPTP-induced proliferative
capacity of progenitor cells in the retina of Ranbp2?/- mice
as uncovered by this study. These differences are likely
caused by the deregulation of the Ranbp2-mediated nucle-
ocytoplasmic shuttling of factors or receptors thereof
controlling cell proliferation or differentiation [69–73]. One
of such factors is the Ranbp2 partner, Ubc9, which is an E2-
ligase implicated in the shuttling and homeostasis of some
orphan receptors [32, 74–78]. It is noteworthy that Ubc9
mediates the repression of pro-inflammatory responses in
microglia and astrocytes by Nurr1 [79], which is associated
with familial late-onset PD [80].
Our studies also reveal metabolic imbalances in the
brain caused by haploinsufficiency of Ranbp2 upon acute
exposure to MPTP. The metabolic footprint uncovered is
significant, because it not only validates and opens new
venues to the identity of some undefined and possibly
shared metabolites modulated by other stressors, such as
phototoxicity [31, 32], but it also delineates disease and
diagnostic predictors of metabolic pathways with relevance
to the understanding of complex clinical and subclinical
phenotypes of human diseases caused by interactions
between the environment and Ranbp2.
In this regard, this study defines the identity of two
medium-chains (pelargonate and caprate) and a long-chain
fatty acid species (arachidate/eicosanoic acid), whose
decreased levels are associated with haploinsufficiency of
Ranbp2. Interestingly, the level of arachidate increases upon
inflammation [81, 82] and as such, its decrease in Ranbp2?/-
upon MPTP treatment may contribute to the suppression of
inflammatory cellular responses observed in the retina of
Ranbp2?/- mice. Further, the modulation of pro-inflam-
matory responses linked to insufficiency of RanBP2 is likely
mediated by the concerted action of multiple metabolites.
5-methylthioadenosine and a-aminoadipate, which are
increased in Ranbp2?/- mice, are additional metabolites
with important anti-inflammatory or anti-proliferative
properties, or both [67, 83, 84].
This work also identifies a set of metabolites from met-
abolic pathways, which are apparently distinct, and are
known to either produce biomarkers of oxidative stress or
present secondary and protective properties against toxic or
injury insults of other etiologies. For example, L-propionyl
carnitine is associated with a reduction in lipid hydroper-
oxides and superoxide anions and the propionyl moiety of L-
propionyl carnitine provides intermediates to the TCA cycle
upon stress conditions and contributes to its therapeutic
benefits [57]. Homocarnosine and 5-methylthioadenosine
are also known to be protective against oxidative stress with
the former acting also as a scavenger for reactive oxygen
species [61, 83]. The increase of these metabolites is
accompanied by disruption of redox homeostasis as
reflected by an increase of diagnostic markers of oxidative
stress, such as dehydroascorbate and ophthalmate, with the
latter acting as biomarker of glutathione depletion [63]. Our
data support that the rise of such ‘‘protective’’ metabolites
likely represents secondary and compensatory responses
and diagnostic markers to noxious insults and that insuffi-
ciency of RanBP2 confers an increased susceptibility to
such neurotoxic damage in the brain.
Finally, the accumulation of various acyl-carnitines,
glucose, lactic acid, and NAD? support a detoxifying efflux
from the mitochondria of metabolites derived from the
incomplete b-oxidation of free fatty acids concomitant with
enhanced anaerobic glycolysis. Current knowledge supports
that these imbalances arise likely from the glia, because
neurons are thought not to utilize b-oxidation of free fatty
acids as energy source [85]. These bioenergetic manifes-
tations assume heightened relevance to our studies, because
MPP? is thought to inhibit directly the NADH:ubiquinone
oxidoreductase of Complex I of the electron transport chain
of the mitochondria [6, 7] and the decrease of the levels of
CoA observed selectively in the striatum of Ranbp2?/-
mice may contribute to the incomplete b-oxidation of free
fatty acids in this brain region. It is not exactly clear how
partial deficits of RanBP2 exacerbate certain bioenergetic
facets of neurotoxic stress-induced manifestations. How-
ever, the work of Neilson et al. and ours support that the
down-regulation of hexokinase I activity by deficits of
RanBP2 [40] or stimulation of the uncoupling of state IV of
oxidative phosphorylation by mutations in Ranbp2 upon
infectious agents and febrile states [33, 86] may espouse a
predilection for higher glucose levels and enhanced anaer-
obic glycolysis upon insufficiency of RanBP2 and exposure
to a variety of stressors.
Collectively, these and other data point toward a number
of RanBP2-mediated metabolic and neurodegenerative
diseases of acute and insidious clinical expressions sharing
strong gene-environment interactions and broader spectra
of metabolic footprints and pathomechanisms than hitherto
realized. For example, PD and acute encephalopathies
often result in striatal injury, but differ by the onset or
progression of injury. Familial necrotic encephalopathies
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caused by mutations in RANBP2 and a number of other
encephalopathies of cerebral organic acid origin are often
precipitated by episodes of febrile and infectious illnesses,
which in turn may elicit fasting and catabolic stress, and
secondarily, excitotoxic, and proinflammatory mechanisms
[33, 87, 88]. Like other acute encephalopathies, infectious
agents may also act as novel etiological agents in Parkinson
disease [89, 90] and systemic metabolic deficits can
directly promote dramatic clinical manifestations with
distinct onsets and selective tissue expressions, such as
age-dependent chorioretinal degenerations (e.g., gyrate
atrophy) [91, 92], and once thought not to share patho-
mechanisms. In this regard, our findings strengthen the
view that mouse models of Ranbp2 are tractable genetic
and physiological tools for the discovery of pathobiological
mechanisms underlying diseases triggered by gene-envi-
ronment interactions.
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